You are here

Positive Data Reported for Subcutaneous Ofatumumab in Multiple Sclerosis

Treatment reduces number of brain lesions in phase II trial (October 10)

Positive results have been reported from a phase II study of a subcutaneous formulation of ofatumumab (Genmab) in relapsing-remitting multiple sclerosis (RRMS).

A total of 232 subjects with RRMS were enrolled in the study. There was a clear separation from placebo on the cumulative number of new gadolinium-enhancing lesions (active brain lesions) over a period of 12 weeks in subjects treated with all doses of ofatumumab compared with subjects treated with placebo (P

The study’s primary objective was to determine whether 3 mg, 30 mg, or 60 mg of subcutaneous ofatumumab can reduce the number of new T1-weighted gadolinium-enhancing brain lesions over 12 weeks compared with placebo in subjects with RRMS. For this endpoint, an analysis of data from weeks 0 to 12 estimated a 65% reduction in the cumulative number of new T1 gadolinium-enhancing lesions for all doses (P P

From weeks 0 to 12, injection-related reactions were the most common adverse events (AEs) and were observed in 52% of subjects receiving ofatumumab compared with 15% of subjects receiving placebo. Five serious AEs were reported; all of these subjects received a 60-mg dose of ofatumumab, and none of the subjects withdrew from the study.

Source: Genmab; October 11, 2013.

Recent Headlines

Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs